Hims & Hers Health, Inc. (HIMS) is getting into the lab testing business, and CEO Andrew Dudum thinks pretty much everyone in America is a potential customer.
The telehealth company announced the launch of Labs, a new service that lets customers track key health markers over time and get actionable guidance on what to do about them. Think heart health, metabolism, hormones, inflammation, and stress—the kind of stuff your doctor might test for during an annual physical, except now packaged as an ongoing subscription with personalized follow-up.
Here's how it works: Customers choose between two annual plans. The Base plan runs $199 per year and includes one blood draw capturing 50 biomarker tests across nine health categories. The Advanced plan costs $499 annually and delivers two blood draws with over 120 biomarker tests across 10 categories. Hims & Hers customers will get their blood drawn at Quest Diagnostics Inc. (DGX) locations—over 1,000 sites nationwide—then receive results and consult with providers on the platform for a personalized plan that could include prescriptions, supplements, or nutrition guidance, Dudum explained to the Wall Street Journal.
The results aren't just a bunch of numbers you'll need to Google. They come with doctor-developed action plans that translate the data into lifestyle guidance and, if appropriate, access to personalized treatment plans through the platform's healthcare providers.
"You know, the size of this market is, I think, every single person in the country," Dudum told the Wall Street Journal, projecting the offering could eventually become a $1 billion business. He emphasized the pricing strategy: "It's a price point that I think the majority of the country can afford."
To put that in context, Quest's comprehensive health profile costs $385 and analyzes more than 75 markers—so Hims & Hers is positioning itself as the more affordable option for ongoing health monitoring.
The company isn't stopping here. Hims & Hers plans to expand Labs over time with at-home testing devices, additional biomarker tests covering areas like bone and brain health, and advanced diagnostics designed to detect chronic and life-threatening conditions early.
This launch comes as Hims & Hers continues to show strong growth. The company reported third-quarter revenue of $598.97 million, topping analyst estimates of $580.24 million. Subscribers climbed to almost 2.5 million, up 21% year-over-year. For the fourth quarter, the company expects revenue between $605 million and $625 million, though that's slightly below the $631.68 million analyst consensus. The company narrowed its fiscal 2025 revenue outlook to a range of $2.335 billion to $2.355 billion, versus the $2.341 billion estimate.
Hims & Hers Health stock was trading up 4.75% at $37.73 on Friday following the announcement.
